Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WL4D
|
|||
| Former ID |
DNCL003412
|
|||
| Drug Name |
STX-100
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Company |
Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin alpha-V/beta-6 (ITGAV/B6) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01371305) STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||
| REF 2 | Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.